Most Read Articles
Jairia Dela Cruz, 3 days ago
Metabolic and bariatric surgery (MBS) leads to large and sustained reductions in, and even reversal of, multiple risk factors for future joint disease in adolescents with severe obesity and musculoskeletal pain, according to data from the Teen Longitudinal Assessment of Bariatric Surgery study.
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.

Deprescribing of acetyle cholinesterase inhibitors safe for patients with severe dementia

06 Jan 2020

Deprescribing acetyl cholinesterase inhibitors (AChEIs) in elderly adults with severe dementia does not appear to result in the occurrence of negative events, a recent study has shown.

The study included 37,106 elderly nursing house residents (aged 65 years; 75.5 percent female) who had severe dementia and were on AChEI medication. Study outcomes included the effects of deprescription on all-cause negative events and on serious falls or fractures.

Almost a third of the participants (31.6 percent) experienced all-cause negative events, while 9.2 percent were hospitalized for falls or fractures. Events were documented over a median follow-up of 226 and 259 days, respectively. The corresponding event rates were 0.56 and 0.15 per person-year.

Visits to the emergency department occurred with the greatest frequency among all-cause negative events (16.1 percent), followed by hospitalizations (8.4 percent) and deaths (7.1 percent).

Patients who had AChEIs deprescribed suffered from a higher rate of all-cause negative events relative to their counterparts who maintained the medication (0.62 vs 0.55 events per person-year). However, the rate of falls or fractures was lower in the former (0.09 vs 0.16 events per person-year).

Unadjusted models confirmed this finding. Deprescribing AChEIs led to a significant increase in the likelihood of all-cause negative events (odds ratio [OR], 1.17, 95 percent confidence interval [CI], 1.11–1.23) and a lower overall risk of falls and fractures (OR, 0.59, 95 percent CI, 0.52–0.66).

However, adjusting for potential confounders attenuated the effect of deprescription on all-cause negative events (adjusted OR, 1.01, 95 percent CI, 0.95–1.07) while retaining its protective effect on falls and fractures (adjusted OR, 0.65, 95 percent CI, 0.56–0.73).

“Our findings suggest that deprescribing AChEIs is a reasonable approach to reduce the risk of serious falls or fractures without increasing the risk for all-cause [negative] events,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 3 days ago
Metabolic and bariatric surgery (MBS) leads to large and sustained reductions in, and even reversal of, multiple risk factors for future joint disease in adolescents with severe obesity and musculoskeletal pain, according to data from the Teen Longitudinal Assessment of Bariatric Surgery study.
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.